Jain P, et al. – This trial dealt with the analysis of the safety profile of intravitreal bevacizumab (Avastin) as an off–label pharmacotherapeutic agent for several ocular conditions. Evidence was obtained with regard to the safety profile of intravitreal bevacizumab (Avastin). Bevacizumab was a safe and economical pharmacotherapeutic agent that could be administered for different ocular disorders. An examination of its safety was required for a developing country like India, owing to the fact that maximum population could not afford the costly ranibizumab as compared to bevacizumab for ocular healthcare.